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Objective: To study the effects of γ-glutamyl carboxylase (GGCX) rs2592551 polymorphism on warfarin dose in
atrial fibrillation patients in Xinjiang region.
Methods: Polymerase chain reaction - restriction fragment length polymorphism and direct sequencing methods
were used to detect the rs2592551 genotype in 269 atrial fibrillation patients with warfarin administration. The
effects of different genotypes on warfarin dose were statistically analyzed.
Results: The rs2592551 polymorphism detection results were 136 cases of wild-type homozygous CC genotype
(50.56%), 115 cases of heterozygous CT genotype (42.75%), 18 cases of homozygous TT genotype (6.69%). The allele
frequency C was 71.93%, T was 28.07%. The stable warfarin dose average was 2.86 ± 0.61 mg/d in patients with CC
genotype, 3.59 ± 0.93 mg/d in patients with CT genotype and 4.06 ± 0.88 mg/d in patients with TT genotype. The
warfarin dose in different genotypes were compared, there was statistically significant difference between CC and
TT, CC and CT (P <0. 05), but the TT and CT showed no significant difference (P > 0.05).
Conclusion: In atrial fibrillation population in Xinjiang, patients with CT and TT genotypes in GGCX gene rs259251
loci required for significantly higher warfarin dose than those with CC genotype. Therefore, rs2592551
polymorphism may one of the factors affecting the warfarin dose in patients with atrial fibrillation.
Keywords: GGCX gene, Atrial fibrillation, Gene polymorphism, WarfarinIntroduction
Atrial fibrillation (AF) is the most common sustained
clinical arrhythmia, the overall incidence of atrial fibrilla-
tion was 0.4%. The incidence of atrial fibrillation in-
creased with age, it can reach up to 10% in people over
75 years. The increased prevalence of atrial fibrillation
was also associated with increased prevalence of coron-
ary heart disease, hypertension, heart failure and other
diseases. In the next 50 years, the atrial fibrillation will
become one of the most popular cardiovascular disease.
Thromboembolism, particular the cerebral embolism
was currently the complication with highest morbidity and
mortality caused by atrial fibrillation. A retrospective sur-
vey of the hospitalized cases of atrial fibrillation in some
areas showed that the prevalence of stroke was 17.5% in
patients with atrial fibrillation [1]. Many studies showed
that the ischemic stroke and complications will greatly* Correspondence: muhuyati@163.com
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stated.increase in atrial fibrillation patients who did not receive
the anticoagulant therapy. Therefore, in order to reduce
the risk of stroke in atrial fibrillation patients, the timely
active anticoagulant was essential in clinical treatment [2].
During atrial fibrillation, the systolic function loss and
long-term heart rate increaseing will lead to heart failure
and increased mortality to 2 times than healthy people
[3]. There were racial differences in atrial fibrillation
causes and risk factors according to the previous study
[4,5]. γ-glutamyl carboxylase (GGCX) was the major en-
zyme affecting the metabolism of warfarin. Warfarin is
the most commonly used anticoagulant in clinical treat-
ment, and GGCX is one of the candidate genes in indi-
vidual differences of response to warfarin [6-10]. In this
study, polymerase chain reaction, restriction fragment
length polymorphism and direct sequencing were used
to genotype the rs2592551 polymorphism in GGCX
gene to, analyze the relation between gene polymorph-
ism and warfarin dose in patients with atrial fibrillation.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 2 Genotype frequencies, warfarin dose and its
comparison in rs2592551 of GGCX gene
N (269) N (%) Warfarin
dose (mg/d)
U value P value
rs2592551
genotype
CC 136(50.56) 2.86 ± 0.61
CT 115(42.75) 3.59 ± 0.93
TT 18(6.69) 4.06 ± 0.88
CC vs TT 353.00 <0.000
CT vs TT 746.00 0.057
CC vs CT 4232.00 <0.000
C 387(71.93)
T 151(28.07)
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The distribution of GGCX gene rs2592551 was in line
with Hardy-Weinberg equilibrium (P > 0.05).
In general clinical data comparison: Age, smoking, and
blood urea nitrogen showed significant differences be-
tween men and women (P <0.05, Table 1), and the other
indicators showed no difference (P > 0.05).
As shown in Table 2, There was statistically significant
difference between CC and TT, CC and CT (P <0. 05) in
warfarin dose, but there was not difference between TT
and CT genotype (P > 0. 05).
γ-glutamyl carboxylase (GGCX) can catalyze the γ-
carboxylating effects of clotting factor II, VII, IX, X. Its role
was dependent on vitamin K and Oxygen (O2) [11]. When
reduced vitamin K and O2 existed, GGCX incorporated
CO2 specifically into glutamic acid residues, the γ-
carboxylated glutamic acid were produced. The vitamin K 2,
3 - epoxide was also produced [12,13]. Glutamic acid resi-
due containing vitamin K-dependent clotting factor II, VII,
IX, X, protein C and protein S should be carboxylated by
GGCX to acquire the activity. Then a series of cascades hap-
pened to cause blood coagulation. Therefore, GGCX was
major enzyme affecting the metabolism of warfarin [14-20].
Atrial fibrillation is the most common arrhythmia in
clinical practice, which can cause the high morbidity and
mortality, but the cause and pathogenesis are still
unclear [21].Table 1 Comparison of the clinical data between male
and female
Parameters Men Women χ2 or t P value
Age (Year) 59.03 ± 14.34 54.60 ± 14.81 2.48 <0.05
Smoking (n,%) 51(33.77) 24(20.33) 5.95 <0.05
Alcohol (n,%) 31(20.53) 15(12.71) 2.86 0.10
BMI (kg/m2 ) 24.09 ± 3.08 24.35 ± 3.13 −0.69 0.50
Height (Cm) 166.34 ± 7.64 165.86 ± 8.37 0.48 0.63
Weight (kg) 69.41 ± 13.56 67.40 ± 12.58 1.24 0.22
Hypertension (n,%) 84(55.63) 61(51.69) 0.41 0.54
CAD (n,%) 87(57.62) 64(54.24) 0.31 0.62
DM (n,%) 83(54.97) 55(46.61) 1.85 0.18
SBP (n,%) 119.34 ± 18.79 116.99 ± 14.70 1.12 0.27
DBP (n,%) 71.40 ± 11.32 73.01 ± 10.84 −1.18 0.24
TG (n,%) 1.41 ± 0.98 1.28 ± 0.70 1.16 0.25
TC (n,%) 4.10 ± 0.96 4.23 ± 1.04 −1.04 0.30
HDL-C (n,%) 0.97 ± 0.31 0.94 ± 0.30 0.62 0.54
LDL-C (n,%) 2.46 ± 0.79 2.49 ± 0.73 −0.41 0.68
FBG (n,%) 6.07 ± 1.97 5.95 ± 1.95 0.48 0.64
BUN (n,%) 342.59 ± 109.03 303.69 ± 86.08 3.18 <0.00
(BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; TG: triglycerides; TC: total cholesterol; HDL-C: high-density
lipoprotein; LDL-C: low-density lipoprotein; FBG: fasting blood glucose;
BUN: blood urea nitrogen).Xinjiang is a multi-ethnic co-populated area, and the
main ethnic groups are Han, Uygur, Kazak, Hui, Kirgiz,
Mongolian, Tajik, etc. Due to geographical conditions, liv-
ing, eating habits in various ethnic groups and genetic
background in Xinjiang, there were obvious differences
between these minor ethnicities and Han population in
other areas. Up to date, although several studies have been
reported the relation between GGCX gene polymorphisms
and warfarin dose, there was no study reporting the effect
of GGCX gene polymorphisms on Warfarin dose in atrial
fibrillation patients in Xinjiang. The previous studies indi-
cated that GGCX gene polymorphism had different de-
grees of impact on warfarin dose. It has been considered
as the major genetic factor influencing warfarin dose.
In this study, we found the stable warfarin dose aver-
age was 2.86 ± 0.61 mg/d in patients with CC genotype,
3.59 ± 0.93 mg/d in patients with CT genotype and
4.06 ± 0.88 mg/d in patients with TT genotype. This
results indicated that the TT genotype carriers in atrial
fibrillation population in Xinjiang required higher dose of
warfarin than patients with CC genotype, which was to
say, the full mutation genotype required more warfarin
than the wild homozygotes genotype. The CT and TT
genotypes required warfarin dose which had no significant
different. There was no significant difference on warfarin
dose between heterozygous (part mutant) genotype and
full mutation genotype.
In conclusion, GGCX gene polymorphism may be one
of the factors affecting the dose of warfarin in patients
with atrial fibrillation in Xinjiang. However, the resultsTable 3 The loci, primer sequences, annealing













Figure 1 The PCR and digestion products of rs2592551. a: rs2592551 PCR product with product length of 381 bp; b: rs2592551 digestion products. 2,
3, 6, 10 were heterozygous CT genotype. 1, 5, 7, 8, 9 were mutated homozygous TT genotype. 4, 7, 8, 9 were homozygous CC wild-type (Due to the 189
and 192 bp enzyme digestion lengths were very close to each other, there showed overlap on the electropherogram showing as one band).
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From January 2009 to December 2012, the inpatients
and outpatients with atrial fibrillation were selected in
the First Affiliated Hospital of Xinjiang MedicalFigure 2 The sequence of CC, CT, and TT genotype, the arrow showeUniversity. The atrial fibrillation was confirmed by ECG
or Holter monitoring, the patients with familial history,
valvular heart disease, congenital heart disease and lung
disease were excluded. 269 atrial fibrillation patients in-
cluding 131 Han population, 83 of Kazak, 53 of Uygur, 1
of Kirgiz, 1 of Mongolian were enrolled. 118 patients
were female with age from 25 to 89 years (54.60 ± 14.81)
And 151 patients were male with age from 22 to 89 yearsd the mutation (a: CC, b: CT, c: TT).
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height, weight, recent warfarin dosage, International nor-
malized ratio (INR) values, and drug administration.
Stable warfarin dose: With the same dose, the 2 con-
secutive INR values in patients were between 1.8 ~ 3.0,
the separated time between 2 times of detection should
be at least more than 7 d [21]. All patients did not have
bleeding or embolic symptoms.
Exclusion criteria: The patients with blood diseases,
coagulation disorders, liver and kidney dysfunction, se-
vere infection, severe heart failure, anemia, cancer and
drugs or food administration which had effects on war-
farin doses were exclude from this study. The protocol
was approved by Medical Ethics Committee of First Af-
filiated Hospital of Xinjiang medical university and all
the patients signed written informed consent.
Methods
Clinical data
The height, weight were measured by specialized
personnel, past history and living habits were obtained
through questionnaires. Body mass index (BMI) = weight /
height2 (kg/m2).
Blood biochemical indicators tests
Serum total cholesterol (TC), high density lipoprotein
cholesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C), triglycerides (TG), uric acid, fasting blood glu-
cose (FBG), blood urea nitrogen, serum creatinine and
other biochemical indicators were measured by inspec-
tion center of the First affiliated hospital of Xinjiang
Medical University. All blood samples were taken in the
morning fasting state.
DNA extraction and PCR amplification
5 ml of fasting venous blood were obtained. After ad-
equate anticoagulation, they were stored at −80°C. The
DNA was extracted by using the whole blood genome ex-
traction kit (TIANGEN Ltd.) Primers were designed using
Primer premier 5.0 software and were synthesized by
Shanghai Sangon Biological Engineering Co., Ltd. The
primers sequence was shown in Table 3. PCR amplifica-
tion was performed in C1000TM Thermal CyclerPCR in-
strument. 20 μl of PCR reaction system contained 10 μl of
PCR Master mix (2×), 0.5 pmol of upstream and down-
stream primers, 7.5 μl of ddH2O, and 2 μl of genomic
DNA. Cycling parameters were as follows: 95°C denatur-
ation for 3 min, 95°C deformation for 30 s, 61.2°C
annealing for 30 s, 72°C extension for 1 min, a total of
35 cycles were include, total extension at 72°C for 5 min.
Genotyping
Polymerase chain reaction-restriction fragment length
polymorphism and direct sequencing methods were usedto genotype. The rs2592551 changed from C to T and one
MbiI (BsrBI) restriction endonuclease was created. After
Mbi digestion, there were two fragments of 189 bp and
192 bp. C allele had no restriction sites and remained a
381 bp fragment. Therefore, the CC genotype was wild
type homozygous and was only one band with fragment
length of 381 bp. CT genotype was heterozygous muta-
tion, which was part mutation and had three fragments of
381,189 and 192 bp, respectively. Because the 189 bp and
192 bp was very close and the bands were overlapped each
other, we only can see that CT heterozygous had two frag-
ments and TT homozygous had one band (Figure 1).
Sequencing
10 of CC type, CT type, and TT type in rs2592551 of
GGCX type gene were randomly selected, respectively,
for sequencing by Shanghai Sangon Biological Engineer-
ing Co., Ltd. The direct sequencing confirmed these ge-
notypes (Figure 2).
Statistical methods
SPSS17.0 statistical package was used for statistical analysis.
The gene counting method was used for allele frequency
and genotype frequencies calculation. Each genotype and
allele frequencies were calculated, the categorical variables
were expressed as percentages. The matching degree of
Hardy-Wrinberg genetic equilibrium in our subjects was
tested with Chi-square. The warfarin dose between different
gender and genotype were compared using rank sum test
namely as U test. P < 0.05 was considered as statistically
significant.
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